Considerations for the Cure Assumption in an NICE Single Technology Appraisal of Nivolumab with Chemotherapy for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer: Evidence Assessment Group Perspective

Giovany Orozco-Leal; Eugenie Evelynne Johnson; Sedighe Hosseinijebeli; Tomos Robinson; Tara Homer; Claire H. Eastaugh; Catherine Richmond; Louise Tanner; Nick Meader; Ryan Kenny; Sheila A. Wallace; Stephen Rice

doi:10.1007/s40273-023-01328-w

Considerations for the Cure Assumption in an NICE Single Technology Appraisal of Nivolumab with Chemotherapy for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer: Evidence Assessment Group Perspective

Giovany Orozco-Leal
, Eugenie Evelynne Johnson
, Sedighe Hosseinijebeli
, Tomos Robinson
, Tara Homer
, Claire H. Eastaugh
, Catherine Richmond
, Louise Tanner
, Nick Meader
, Ryan Kenny
, Sheila A. Wallace
, Stephen Rice

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English
Pages (from-to)	133-136
Number of pages	4
Journal	PharmacoEconomics
Volume	42
Issue number	2
DOIs	https://doi.org/10.1007/s40273-023-01328-w
State	Published - Feb 2024
Externally published	Yes

ASJC Scopus Subject Areas

Pharmacology
Health Policy
Public Health, Environmental and Occupational Health

Access to Document

10.1007/s40273-023-01328-w

Cite this

Orozco-Leal, G., Johnson, E. E., Hosseinijebeli, S., Robinson, T., Homer, T., Eastaugh, C. H., Richmond, C., Tanner, L., Meader, N., Kenny, R., Wallace, S. A., & Rice, S. (2024). Considerations for the Cure Assumption in an NICE Single Technology Appraisal of Nivolumab with Chemotherapy for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer: Evidence Assessment Group Perspective. PharmacoEconomics, 42(2), 133-136. https://doi.org/10.1007/s40273-023-01328-w

Considerations for the Cure Assumption in an NICE Single Technology Appraisal of Nivolumab with Chemotherapy for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer: Evidence Assessment Group Perspective. / Orozco-Leal, Giovany; Johnson, Eugenie Evelynne; Hosseinijebeli, Sedighe et al.
In: PharmacoEconomics, Vol. 42, No. 2, 02.2024, p. 133-136.

Research output: Contribution to journal › Comment/debate › peer-review

Orozco-Leal, G, Johnson, EE, Hosseinijebeli, S, Robinson, T, Homer, T, Eastaugh, CH, Richmond, C, Tanner, L, Meader, N, Kenny, R, Wallace, SA & Rice, S 2024, 'Considerations for the Cure Assumption in an NICE Single Technology Appraisal of Nivolumab with Chemotherapy for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer: Evidence Assessment Group Perspective', PharmacoEconomics, vol. 42, no. 2, pp. 133-136. https://doi.org/10.1007/s40273-023-01328-w

Orozco-Leal G, Johnson EE, Hosseinijebeli S, Robinson T, Homer T, Eastaugh CH et al. Considerations for the Cure Assumption in an NICE Single Technology Appraisal of Nivolumab with Chemotherapy for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer: Evidence Assessment Group Perspective. PharmacoEconomics. 2024 Feb;42(2):133-136. doi: 10.1007/s40273-023-01328-w

@article{e7f068641db848f09e1923b22e2fa884,

title = "Considerations for the Cure Assumption in an NICE Single Technology Appraisal of Nivolumab with Chemotherapy for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer: Evidence Assessment Group Perspective",

author = "Giovany Orozco-Leal and Johnson, \{Eugenie Evelynne\} and Sedighe Hosseinijebeli and Tomos Robinson and Tara Homer and Eastaugh, \{Claire H.\} and Catherine Richmond and Louise Tanner and Nick Meader and Ryan Kenny and Wallace, \{Sheila A.\} and Stephen Rice",

year = "2024",

month = feb,

doi = "10.1007/s40273-023-01328-w",

language = "English",

volume = "42",

pages = "133--136",

journal = "PharmacoEconomics",

issn = "1170-7690",

publisher = "Adis International Ltd.",

number = "2",

}

TY - JOUR

T1 - Considerations for the Cure Assumption in an NICE Single Technology Appraisal of Nivolumab with Chemotherapy for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer

T2 - Evidence Assessment Group Perspective

AU - Orozco-Leal, Giovany

AU - Johnson, Eugenie Evelynne

AU - Hosseinijebeli, Sedighe

AU - Robinson, Tomos

AU - Homer, Tara

AU - Eastaugh, Claire H.

AU - Richmond, Catherine

AU - Tanner, Louise

AU - Meader, Nick

AU - Kenny, Ryan

AU - Wallace, Sheila A.

AU - Rice, Stephen

PY - 2024/2

Y1 - 2024/2

UR - https://www.scopus.com/pages/publications/85177078590

UR - https://www.scopus.com/pages/publications/85177078590#tab=citedBy

U2 - 10.1007/s40273-023-01328-w

DO - 10.1007/s40273-023-01328-w

M3 - Comment/debate

C2 - 37985576

AN - SCOPUS:85177078590

SN - 1170-7690

VL - 42

SP - 133

EP - 136

JO - PharmacoEconomics

JF - PharmacoEconomics

IS - 2

ER -

Considerations for the Cure Assumption in an NICE Single Technology Appraisal of Nivolumab with Chemotherapy for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer: Evidence Assessment Group Perspective

ASJC Scopus Subject Areas

Access to Document

Other files and links

Cite this